Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the DEF14 C:
"Plans, arrangements, commitments or understandings for the issuance of the additional shares of Common Stock.
On November 20, 2013, we entered into an Investment Banking Agreement with Cassel Salpeter & Co. (“CSC”), who will act as exclusive third party financial advisor in connection with investment banking matters. The term of the Investment Banking Agreement shall be for a period of twenty four months unless terminated or extended in accordance with its terms. Part of these services may involve the closing of a Mezzanine Financing consisting of non-convertible subordinated debt and/or sale of equity securities. In the event a Mezzanine Financing is closed, additional securities may be issued. There are no definitive agreements at present for a Mezzanine Financing.
Apart from the above, there are currently no plans, arrangements, commitments or understandings for the issuance of the additional shares of Common Stock which are proposed to be authorized. "
If they state that it is fully funded by BHRT and assume it will take about a year to complete enrollment... I believe they are already taking cost into consideration. IMO
I don't understand why we are "waiting" for Myocell funding news... It clearly states that Myocell is "fully funded by BioHeart" and that enrollment will continue and that it will take about a year to complete enrollment. A year being exactly this month. If you remember correctly Kristen Comella clearly stated on the blog that she recently posted that enrollment would be kept under wraps until entirely complete and patients have been treated because they are dealing with a control group as well. I think that any day now we should be getting a PR on complete enrollment/treatment. IMO
Sorry I could not post the link to Kristen Comella's blog as the stemcellceo website is down.
Sunrise, FL – July 2nd, 2013 - Bioheart, Inc. (BHRT.OB) announced today the successful enrollment and randomization of the first patient in the Phase III MIRROR Trial using MyoCell® or muscle derived stem cells.
The MIRROR trial is fully funded by Bioheart and will be conducted at up to 35 centers in North and South America. The trial is designed to enroll up to 126 patients over a 12 month time period. The first patient has been enrolled in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This study will complement the data completed in the Phase II/III MARVEL trial on patients with congestive heart failure (CHF). Patients are randomized into either the treatment (2/3) or placebo (1/3) arm. All patients will receive delivery into the damaged areas of the heart using the MyoCath® Catheter. Data endpoints will include safety, exercise capacity, quality of life, and ejection fraction at 3 months and 6 months. Kristin Comella, Bioheart’s Chief Science Officer said “We are hoping to achieve results similar to those from the MARVEL trial in which patients improved almost 100 meters over placebo in their exercise capacity test. We believe this therapy can address an unmet need for cardiac patients.”
The FDA has placed a hold on the request for an Expanded Access protocol using MyoCell in part because the proposed expanded access study would likely interfere with the clinical development of MyoCell and/or interfere with developing market approval. Bioheart intends to continue enrollment in the MIRROR trial while hold items are addressed with the FDA. In addition, Bioheart plans to initiate part 2 of the MARVEL trial using the J&J MyoStarTM Catheter to deliver MyoCell to CHF patients.
MMs held it back... Far too obvious.
I think it's coming before seven eleven.
Ok so now we have 3 huge catalyst in the oven almost completely ready to be served IMO. 1. Phase 1 Adipocell trial results... 2. Substantial if not exponential revenue increases in the next 10-Q... And 3. The holy grail Myocell funding announcement. GLTA
I agree, great news this morning.
I don't think this was the doing of the new CEO... This had to have been in the works for a while, I credit Ted Myles.
BioHearts various treatments are on many different radars.
Agreed.
Easy pickings.
The stock is up 193% year to date... How is that toxic??
Yes, we've known about the "cowboy" for a while now but, having the information about him published and solidified in an article is what we didn't have before... Therefore it was all speculation till now.
Thanks skulbone. The finding of this is really hard to accept as reality for me, especially after so much work has been put into keeping the TLD under wraps. This is actual factual published data and in one form or another "results". GLTA, especially longs. Monday should be interesting.
Wait I have many questions.... Who found this? And why was it initially allowed to be published?
http://www.bioheartinc.com/assets/press/BIOHEARTANNOUNCESJOINTVENTUREINSOUTHAFRICA.pdf
"Dr. Walter Bell has been providing Bioheart therapies to patients in South Africa suffering from degenerative diseases since the end of 2013. Under this new agreement, the facilities in South Africa will be expanded to provide cell culture expansion and cryopreservation to local patients. Bioheart can multiply and preserve an individual’s cells in
sub-zero temperatures for future treatments as required."
Sounds to me like we already had a partnership that brought in revenue and now with the "new agreement" and expansion, we can expect even more revenue as the awareness of the BioHeart therapies grow. Only reason for the "new agreement" IMO and for the expansion is if necessary. Therefore expect increased revenue coming from that JV in the next 10Q IMO.
Yes definitely. Also, last PR about Myocell was last July 2013 in which it was stated that phase 3 enrollment would take about 1 year... 1 year is next month, funding announcement coming soon including enrollment completed PR??
Next big catalyst is around the corner. Adipocell, angel phase 1 completion results and initiation of phase 2
Exactly.
Well, last run up it had a starting point of .01 and it hit .08 cents. Being extremely optimistic and mathematical if the new starting point is .03 and the next run up correlates the previous one than it's say .24 cents (8X3) but being more realistic... I do see this breaking .10 cents on 12 month trial phase 1 Adipocell results... And the major kicker I believe will be funding news for Myocell phase 3 which IMO would put the company above 1$ and allowing I believe, correct me of I'm wrong, BioHeart to up list back on the NASDAQ. I would love to qualify back on the Nasdaq without having to RS. IMO
BioHeart is in stride now!!
Purchased at .04?!
No one is looking to sell. That's a great sign. Today is the beginning of the end of these lows.
Not if you look at the big picture... Go look again.
I like that, "BS" also known as Biotech Success.
Here we go!!! Go BHRT!
I'm hoping for a run up toward the maxim target price point of .45 I would prefer partnerships vs buyouts because I wouldn't know what the intention of the buying company would be. I see exponential potential growth once this company partners and initiates a promising phase 2 based on phase 1 results and in combination with the other things in the pipeline. Remember we've got a platelet program looking to partner with government.
Had no*
Part of the settlement agreement was that the shares given to A/G had not voting right... They cannot be on the board.
How did you come up with those numbers lasers?
IMO if they have chosen to (and announced) move forward with phase 2 trials... That is an indirect announcement that financing options are available and or locked in. Phase 2 trials are far more expensive than phase 1 and I do not believe they can accomplish initiation alone without a finance deal. What they will not do is PR finance news without RS and up list to Nasdaq.
12 month data for completion of phase 1 adipocell coming very soon. With that, maybe peer review and phase 2 details.
It's not your link it's the website that is down.
Don't expect news of JV or partnership or any type of funding before the RS.
Yes it is life threatening, it threatens your quality of life.
Some would rather die on their feet than live on their knees... Think about that.
Thanks for your response but that doesn't answer my question... I'm well aware of what insider information is. I'm asking what insider information is being referred too
How is that insider information?
They're in the Q&A part right now so I assume it's almost over. Nothing key has been said besides the initiation of the mmd trial at UCLA and the settlements
I'm still on.